Navamedic ASA – Mandatory notification of trade by primary insider

Oslo, 15 March 2024: Reference is made to the stock exchange announcement published earlier today, on 15 March 2024 by Navamedic ASA (the "Company" or "Navamedic"), regarding the board of directors' resolution to increase the Company's share capital with NOK 59,200 by the issuance of 80,000 new shares, in order to facilitate the settlement of exercise of 80,000 share options in the Company.

The following primary insiders have today exercised share options:

Lars Hjarrand, CFO of Navamedic, has today, on March 15 2024, exercised 50,000 share options in the Company under his option agreement from 2020 and subscribed for 50,000 new shares in the Company. Following the option exercise and subscription of the new shares, Lars Hjarrand holds 335,882 shares and 200,000 options in the Company.

Karianne Femtehjell Olsen, Sales and Marketing Director of Navamedic, has today, on March 15 2024, exercised 30,000 share options in the Company under her option agreement from 2020 and subscribed for 30,000 new shares in the Company. Following the option exercise and subscription of the new shares, Karianne Femtehjell Olsen holds 30,050 shares and 200,000 options in the Company.

Please refer to the attached notification of trading for further details.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.